Chemonucleolysis

StudyID no.EV1EV2 (%)EV3EVRSB1SB2SB3SB4 (%)SB5SB6SB7SB8SB9SBRDB1aDB1bDB2DB3DB4DBRPB1PB2PB3PBRAB1AB1aAB2 (%)AB3AB4ABRGR
Chemonucleolysis vs disc surgery
Krugluger, 20004635?NR?WRCT??<60?++??W+++??MNAW+80–100??WW
van Alphen, 19894743+60–79+SRCT±?<60?++?M+?WNAW+80–100++SM
Javid, 19954844±NR±MCCS60–79±+?W+?WNAW+80–100++SW
Postacchini, 19864945±NR±MNon-RCT<60?±W+?WNAW?80–100WW
Norton, 19865047NR±WCCS<60+?W???WNAWNANANANANANAW
Dabezies, 19785148±NR±MCCS<60???W+WNAW??Cannot tell+?WW
Stula, 199052 (German language)49?NR±WRCT??<60?++?M???WNAW+80–100+WW
Tregonning, 19915361±NA±MHCS<60?±?W+++?MNAW?80–100+MW
Lagarrigue, 199154 (French language)117±60–79±MCCS<60+W++±??WNAW+80–100++SW
Lavignolle, 198755 (French language)129?NR±WRCT??<60?++?W±±±??WNAW+80–100++SW
Hoogmartens, 197656132±NR±MHCS<60??WNA?WNAWNANANANANANAW
Zeiger, 198758150?NR?WCCS<60?????W++?WWNA?NA+?WW
Watts, 197559160?NR±WCCS<60?+?W+??WNAW+80–100++SW
Crawshaw, 198460166±NR±MRCT??<60?++?M+??WNAW+80–100++SW
Bouillet, 198361183±NA+MCCS<60?WWNAWNANANANANANAW
Bonafe,199375 (French language)441?NR±WCCS<60???W+++??WNAW+80–100++SW
Brown, 198976453?NR±WCCS<60?++?W++++?MNAW±+80–100+WW
Buric, 200577454?NR+WNon-RCT<60++?W+++NAMNAW?80–100++SW
Dei–Anang, 199079 (German language)471?NR±WCCS<60??W+??WNAWNANANANANANAW
Muralikuttan, 199285593±60–79+MRCT+?80–100+++NA?M+++??MNAW?80–100++MM
Revel, 199388617?NR±WRCT+?60–79±++?M+++??MNAW+80–100+WM
Steffen,199990 (German language)641?NR±WRCT??<60?++?M++++?MNAW+80–100++SW
Weinstein, 19869267260–79WCCS<60??W++NA?WNAW+80–100+WW
Ejeskar, 198396727±NR±MRCT??<60?++?M+??WNAW+80–100++SW
Alexander, 1989103884±NRWCCS<60?+?W++±??WNANANAW+80–100++SW
Lee,1996104 (German language)889?NR±WCCS<60?+?W+??WNAW??Cannot tell+?WW
Watters,1988105893±NR±WNon-RCT<60??W?WNAW+80–100++SW
Chemonucleolysis vs epidural/intradiscal injection
Graham, 197614450NRWNon-RCT<60???W++?M+MNA80–100++SW
Bourgeois, 1988160 (French language)447?NR+WRCT+±<60?++?M++?W++?M+80–100++SM
Bontoux, 1990168 (French language)720?NR±WRCT+?<60?++?M++?M+?M+80–100++SM
Gallucci, 2007170729?NR±WRCT??<60?++??M±±++?M+M+80–100++SM
Chemonucleolysis vs inactive control
Gogan, 199220555±NR+MRCT+?60–79±++?M++++?M?W?±80–100+MM
Schwetschenau, 1976206236±<60MRCT++60–79±++?M++?M++?M+80–100++SS
Feldman, 1986207 (French language)244±NR±MRCT??80–100±++?M+++??M+?M??80–100++MM
Dabezies, 1988209726?NR+WRCT±+<60?++?M++?M++?M?+60–79+WM
Javid, 1983210738?NR+WRCT+±<60?++?M++±M++?M+80–100+SM
Chemonucleolysis vs manipulation
Burton, 2000208723?NR+WRCT80–100+++NA?M+++++SNAW±60–79+MM
Chemonucleolysis vs mixed treatments
Khoromi, 2007214534±80–100+SRCT (crossover)++80–100+++++S++++?M+++S?+<60+WM

−, no; ±, partial; +, yes; ?, unclear; M, moderate; NA, not applicable; NR, not reported; S, strong; W, weak.

From: Appendix 5, Quality assessment of included clinical effectiveness studies

Cover of The Clinical Effectiveness and Cost-Effectiveness of Management Strategies for Sciatica: Systematic Review and Economic Model
The Clinical Effectiveness and Cost-Effectiveness of Management Strategies for Sciatica: Systematic Review and Economic Model.
Health Technology Assessment, No. 15.39.
Lewis R, Williams N, Matar HE, et al.
Southampton (UK): NIHR Journals Library; 2011 Nov.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.